Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16055
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCheung, AS-
dc.contributor.authorHoermann, R-
dc.contributor.authorDupuis, P-
dc.contributor.authorLim Joon, D-
dc.contributor.authorZajac, J-
dc.contributor.authorGrossmann, M-
dc.date2016-06-23-
dc.date.accessioned2016-06-27T05:30:53Z-
dc.date.available2016-06-27T05:30:53Z-
dc.date.issued2016-06-23-
dc.identifier.citationEuropean Journal of Endocrinology 2016; Jun 23 pii: EJE-16-0200en_US
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/16055-
dc.description.abstractOBJECTIVE: While androgen deprivation therapy (ADT) has been associated with insulin resistance and frailty, controlled prospective studies are lacking. We aimed to examine relationships between insulin resistance and frailty with body composition and testosterone. DESIGN: Case-control prospective study. METHODS: 63 men with non-metastatic prostate cancer newly commencing ADT (n=34) and age-matched prostate cancer controls (n=29) were recruited. Main outcomes were insulin resistance (HOMA2-IR), Fried's frailty score, body composition by dual x-ray absorptiometry and short physical performance battery (SPPB) measured at 0, 6 and 12 months. A generalised linear model determined the mean adjusted difference [95% CI] between groups. RESULTS: Compared to controls over 12 months, men receiving ADT had reductions in mean total testosterone level (14.1 to 0.4nmol/L, p<0.001), mean adjusted gain in fat mass of 3530g [2012, 5047], p<0.02 and loss of lean mass of 1491g [181, 2801], p<0.02. Visceral fat was unchanged. HOMA2-IR in the ADT group increased 0.59 [0.24, 0.94], p=0.02 which was most related to the increase in fat mass (p=0.003), less to lean mass (p=0.09) or total testosterone (p=0.088). Frailty increased with ADT (p<0.0001), which was related to decreased testosterone (p=0.028), and less to fat mass (p=0.056) or lean mass (p=0.79). SPPB was unchanged. CONCLUSIONS: ADT is associated with increased insulin resistance and frailty within 12 months of commencement, independently of confounding effects of cancer or radiotherapy. Insulin resistance appears to be mediated by subcutaneous or peripheral sites of fat deposition. Prevention of fat gain is an important strategy to prevent adverse ADT-associated cardiometabolic risks.en_US
dc.titleRelationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate canceren_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleEuropean Journal of Endocrinologyen_US
dc.identifier.affiliationDepartment of Medicine Austin Health, The University of Melbourne, Heidelberg, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27340081en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
crisitem.author.deptRadiation Oncology-
crisitem.author.deptEndocrinology-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.